Gregory Ciongoli
Net worth: 16 M $ as of 30/08/2026
Net worth: 16 M $ as of 30/08/2026
Gregory A. Ciongoli is the founder of Adiumentum Capital Management LLC.
Mr. Ciongoli is Chairman at Atara Biotherapeutics, Inc. starting in 2025.
Mr. Ciongoli is Director at Zymeworks, Inc. starting in 2025.
Mr. Ciongoli is Independent Director at REGENXBIO, Inc. starting in 2026.
Mr. Ciongoli was Partner at The Baupost Group LLC.
Mr. Ciongoli earned an MBA from Harvard Business School.
Mr. Ciongoli completed undergraduate studies at Woodrow Wilson School of Public & International Affairs.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZYMEWORKS INC. 0.7% | 11/01/2026 | 493,500 ( 0.7% ) | 15 M $ | 30/08/2026 |
REGENXBIO, INC. 0.18% | 26/08/2026 | 118,035 ( 0.18% ) | 1 M $ | 30/08/2026 |
| 08/06/2026 | 12,000 ( 0.12% ) | 106 800 $ | 30/08/2026 |
| Companies | Position | Start |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chairman | 02/09/2025 |
| ZYMEWORKS INC. | Director/Board Member | 10/08/2025 |
| REGENXBIO INC. | Director/Board Member | 24/08/2026 |
| GOSSAMER BIO, INC. | Director/Board Member | 15/09/2026 |
| Companies | Position | End |
|---|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Finance |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Woodrow Wilson School of Public & International Affairs
Woodrow Wilson School of Public & International Affairs Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Select your edition
All financial news and data tailored to specific country editions